AAN 2019 Plenary Session Highlights Research With Implications for Patient Care From Multiple Society Meetings

Related Articles:

• Long-Term Efficacy for Parkinsonism and Safety of Zonisamide in Patients With Lewy Body Dementia Examined May 8, 2019 The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019. PHILADELPHIA — Zonisamide showed long-term efficacy for parkinsonism and safety in patients…
• Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. April 30, 2019 Related ArticlesClonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. J Neurol Sci. 2019 Apr 23;401:81-86 Authors: Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B Abstract BACKGROUND: Clonazepam is considered to be a first-line treatment for rapid eye movement sleep-related behavior disorder (RBD) in Parkinson's disease (PD). The purpose of this…
• CVT-301 Improves Movement when Parkinson’s Symptoms Re-emerge During Day, Trial Shows June 9, 2017 CVT-301 significantly improves movement in Parkinson’s disease patients at times of the day when the impact of other therapies diminishes, according to a Phase 3 clinical trial. The impact of a Parkinson’s treatment varies during the day. It is often most effective right after a patient takes it, and least effective when much of its punch has worn off hours…
• Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. April 26, 2019 Related ArticlesSafety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS One. 2019;14(4):e0214364 Authors: Novak P, Pimentel Maldonado DA, Novak V Abstract Parkinson disease (PD) is associated with cognitive impairment. We aimed to determine the effects of intranasal insulin (INI) on cognition and motor performance in PD.…
• Amantadine May Optimize Levodopa Regimen in Parkinson Disease Treatment May 8, 2019 The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019. PHILADELPHIA, PA — Long-term adjunctive amantadine (Gocovri®, Adamas Pharmaceuticals) treatment for individuals…
• Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. June 30, 2019 Related ArticlesDeutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017 08;4(8):595-604 Authors: Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH Abstract BACKGROUND: Tardive dyskinesia results from exposure to dopamine…
• Lowering Iron Levels in Brain May Help Treat Parkinson’s, Trial in People with PKAN Says June 18, 2019 Binding to, or chelating, toxic levels of iron in the brain can slow the progression of a neurodegenerative disorder known as pantothenate kinase-associated neurodegeneration (PKAN), results from a Phase 3 trial show. These findings may be relevant for other neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s and multiple sclerosis, which are also associated with high levels of iron in the…
• SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. March 29, 2019 SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019 Mar 27;: Authors: Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, Ochudlo S, Banach M, Pagan F, Flatau-Baqué B, Csikós J, Cairney CJ, Blitzer A Abstract OBJECTIVE: This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of chronic…
• #AANAM – Opicapone Can Prolong ‘On-Time’ Levopoda Provides, Data from Phase 3 Trials Show May 6, 2019 Once-daily opicapone can prolong the time during which treatment with levopoda, a standard therapy, effectively prevents motor symptom fluctuations in people with Parkinson’s disease, results from two international Phase 3 studies show. The findings, “Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase 3 Studies,” were presented during the 2019 Annual Meeting of the American Academy of Neurology (AAN), now…
• Study proves the effectiveness of Parkinson’s drug apomorphine May 11, 2017 Results from the 12-week TOLEDO study – which tested the effectiveness of APO-go®/MOVAPO® (apomorphine) on Parkinson’s patients whose symptoms could not be controlled with standard therapies – showed that patients treated with the infusion had a significantly greater improvement in ‘off’ time, compared with those taking the placebo. The reduction in ‘off’ time was achieved without an increase in dyskinesias and…
• Epigallocatechin Gallate Shows No Significant Benefit for Multiple System Atrophy August 2, 2019 Orally administered epigallocatechin gallate treatment showed no significant benefits in modifying disease progression for people with multiple system atrophy, according to clinical trial results published in The Lancet Neurology. Investigators designed a randomized, double-blind, placebo-controlled clinical trial (PROMESA; ClinicalTrials.gov Identifier: NCT02008721) to test the safety and efficacy of using epigallocatechin gallate for the treatment of multiple system atrophy in people with…
• Trial Investigating Pimavanserin for Dementia-Related Psychosis Stopped Early Due to Positive Findings September 12, 2019 A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis. The HARMONY trial (N=356) was evaluating the safety and efficacy of pimavanserin, an atypical antipsychotic, in preventing a relapse of psychotic symptoms in patients with dementia-related psychosis who were stabilized after 12 weeks…
• Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. July 30, 2019 Related ArticlesOnabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018 02 13;90(7):e559-e564 Authors: Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J Abstract OBJECTIVES: To test the safety and efficacy of onabotulinum toxin-A (BoNT-A) injections into the masseter and temporalis muscles in patients with symptomatic sleep bruxism. METHODS: Participants 18 to 85 years old…
• #AAN2018: Biogen’s BIIB054 Shows Positive Data in Phase 1 Parkinson’s Trial April 18, 2018 Parkinson’s treatment candidate BIIB054 was well-tolerated and had a favorable pharmacological profile in preliminary Phase 1 clinical results. Biogen will present those results at the 2018 American Academy of Neurology ANN Annual Meeting in Los Angeles, California, April 21-27. Parkinson’s News Today will be covering the conference. The presentation “Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of AntiAlpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease,” will be…
• Antiviral Therapy May Reduce Risk for Parkinson Disease in Chronic HCV June 25, 2019 Patients with hepatitis C virus (HCV) who are treated with interferon (IFN)-based antiviral medications have a significantly reduced risk of developing Parkinson disease compared with patients who do not receive this treatment, according to study results published in JAMA Neurology. The investigators of this population-based cohort study sought to explore the association between IFN-based antiviral therapy and the development of…
• Memantine for dementia. March 21, 2019 Related ArticlesMemantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3:CD003154 Authors: McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J Abstract BACKGROUND: Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is…
• Recently published results of a GDNF intraputaminal infusion clinical trial March 5, 2019 A clinical trial, is by definition an experiment or a test — an effort to determine if something works, or doesn’t.  Sometimes, although the intended outcome of a clinical trial may fall short of expectations, the results are nevertheless intriguing and may spark additional avenues of investigation. Such is the case in a clinical trial of glial cell line derived…
• Deferiprone May Slow Disease Progression in Pantothenate Kinase-Associated Neurodegeneration July 24, 2019 Deferiprone was well-tolerated, safe, and appears to slow disease progression in pantothenate kinase-associated neurodegeneration (PKAN), according to research published in The Lancet. In this 18-month, randomized, double-blind, placebo-controlled trial, investigators followed a pre-planned 18-month open-label extension study that included patients with PKAN (n=88). Using a centralized computer random number generator and with stratification based on age group at the onset…
• FDA Accepts Opicapone NDA for Adjunctive Treatment of Parkinson Disease July 15, 2019 Neurocrine Biosciences announced that the Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for opicapone, an investigational once daily selective catechol-O-methyltransferase (COMT) inhibitor, for adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing OFF episodes. Opicapone works by decreasing the conversion rate of levodopa into 3-O-methyldopa thus prolonging the clinical effects and availability of levodopa…
• Nocebo response in Parkinson's disease: A systematic review and meta-analysis. May 20, 2019 Nocebo response in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2019 Apr 20;: Authors: Leal Rato M, Duarte GS, Ferreira AN, Alves M, Mainoli B, Teodoro T, Mestre TA, Costa J, Ferreira JJ Abstract OBJECTIVE: To estimate the magnitude of the nocebo response in Parkinson's disease and explore possible associations with study characteristics. METHODS: Databases were searched…